MCID: OPD001
MIFTS: 43

Opioid Abuse

Categories: Mental diseases

Aliases & Classifications for Opioid Abuse

MalaCards integrated aliases for Opioid Abuse:

Name: Opioid Abuse 12 56 15 74
Opioid-Related Disorders 45

Classifications:



External Ids:

Disease Ontology 12 DOID:11206
ICD9CM 36 305.5
MeSH 45 D009293
SNOMED-CT 69 5602001
ICD10 34 F11.1
UMLS 74 C0029095

Summaries for Opioid Abuse

Disease Ontology : 12 A substance abuse that involves the recurring use of opioid drugs despite negative consequences.

MalaCards based summary : Opioid Abuse, also known as opioid-related disorders, is related to opiate dependence and neonatal abstinence syndrome. An important gene associated with Opioid Abuse is OPRM1 (Opioid Receptor Mu 1), and among its related pathways/superpathways are Peptide ligand-binding receptors and DREAM Repression and Dynorphin Expression. The drugs Buprenorphine and Guaifenesin have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and skin, and related phenotypes are behavior/neurological and integument

Related Diseases for Opioid Abuse

Graphical network of the top 20 diseases related to Opioid Abuse:



Diseases related to Opioid Abuse

Symptoms & Phenotypes for Opioid Abuse

MGI Mouse Phenotypes related to Opioid Abuse:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.8 GRIN3B MAPK10 OPRD1 OPRK1 OPRL1 OPRM1
2 integument MP:0010771 9.55 OPRD1 OPRK1 OPRL1 OPRM1 PDYN
3 nervous system MP:0003631 9.5 CCK MAPK10 OPRD1 OPRK1 OPRL1 OPRM1
4 no phenotypic analysis MP:0003012 9.02 CCK MAPK10 OPRD1 OPRM1 PDYN

Drugs & Therapeutics for Opioid Abuse

Drugs for Opioid Abuse (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 344)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 52485-79-7 40400 644073
2
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 93-14-1 3516
3
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 76-99-3 4095
4
Bupivacaine Approved, Investigational Phase 4,Phase 2,Phase 3 2180-92-9, 38396-39-3 2474
5
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 437-38-7 3345
6
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 62-31-7, 51-61-6 681
7
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 16590-41-3 5360515
8
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 64-17-5 702
9
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 1,Phase 2,Not Applicable,Early Phase 1 76-42-6 5284603
10
Naloxone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 465-65-6 5284596
11
Morphine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 57-27-2 5288826
12
Acetaminophen Approved Phase 4,Phase 2,Phase 1,Early Phase 1,Not Applicable 103-90-2 1983
13
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
14
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3 113775-47-6 68602 5311068
15
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
16
Acetazolamide Approved, Vet_approved Phase 4,Phase 2 59-66-5 1986
17
Remifentanil Approved Phase 4,Phase 3 132875-61-7 60815
18
Ketamine Approved, Vet_approved Phase 4,Phase 3,Phase 2 6740-88-1 3821
19
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
20
Norepinephrine Approved Phase 4 51-41-2 439260
21
Cocaine Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-36-2 446220 5760
22
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
23
Ribavirin Approved Phase 4,Phase 3,Not Applicable 36791-04-5 37542
24
Buspirone Approved, Investigational Phase 4,Phase 1 36505-84-7 2477
25
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
26
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1401-55-4
27
Nicotine Approved Phase 4,Phase 1,Phase 2 54-11-5 942 89594
28
Gabapentin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 60142-96-3 3446
29
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
30
Rifapentine Approved, Investigational Phase 4 61379-65-5 6323497
31
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
32
Velpatasvir Approved, Investigational Phase 4 1377049-84-7 67683363
33
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
34
Cobicistat Approved Phase 4 1004316-88-4
35
Oxymorphone Approved, Investigational, Vet_approved Phase 4,Phase 2 76-41-5 5284604
36
Ibuprofen Approved Phase 4,Phase 2,Early Phase 1 15687-27-1 3672
37
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
38 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Analgesics, Opioid Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Narcotics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Narcotic Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
44 Opiate Alkaloids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
45
Heroin Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 5462328
46 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Antitussive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Chlorpheniramine, phenylpropanolamine drug combination Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Anesthetics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
50 Anesthetics, Local Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 612)
# Name Status NCT ID Phase Drugs
1 Buprenorphine and Integrated HIV Care Evaluation Unknown status NCT00124358 Phase 4 Buprenorphine
2 Integrating Buprenorphine Into HIV Treatment Unknown status NCT00241930 Phase 4
3 Transfer From Methadone to Buprenorphine Maintenance Treatment Using Buprenorphine Patches Unknown status NCT00750217 Phase 4 Buprenorphine patch and sublingual tablets
4 Multimodal Pain Management for Cesarean Delivery Completed NCT02922985 Phase 4 Intravenous acetominophen;Ketorolac, intramuscular;Bupivacaine, subcutaneous;Normal saline
5 Feasibility Study of Take-Home LAAM Medication - 3 Completed NCT00000300 Phase 4 LAAM
6 Influence of Dexmedetomidine and Lidocaine on Opioid Consumption in Laparoscopic Intestine Resection Completed NCT02616523 Phase 4 Dexmedetomidine;Lidocaine;Fentanyl
7 Administration of Acetazolamide to Prevent Remifentanil Induced Hyperalgesia Completed NCT02992938 Phase 4 Acetazolamide;Placebo Oral Tablet
8 Depot Naltrexone Mechanism of Action in Heroin Dependent Patients Using fMRI and SPECT Completed NCT01471145 Phase 4 Naltrexone
9 A Comparison of PR Oxycodone/Naloxone and PR Oxycodone After Cardiac Surgery Completed NCT01374763 Phase 4 Oxycodone;Prolonged-release oxycodone/naloxone
10 Neurocognitive Effects of Opiate Agonist Treatment Completed NCT01733693 Phase 4 Buprenorphine;Methadone
11 Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 In Buprenorphine/Naloxone Treated Opioid Dependent Population Completed NCT02038790 Phase 4 Suboxone Sublingual Film;Zubsolv sublingual tablets
12 Integrating Buprenorphine Into the SFGH AIDS Program Completed NCT00263458 Phase 4
13 Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid Dependence Completed NCT01903005 Phase 4 Higher bioavailability BNX sublingual tablets
14 A Study of VIVITROL in the Prevention of Re-arrest and Re-incarceration Completed NCT01453374 Phase 4 VIVITROL 380mg
15 Multicentre Trial of Suboxone in Opiate-dependent Subjects in Taiwan Completed NCT00901875 Phase 4 Buprenorphine + naloxone (Suboxone);Buprenorphine + naloxone (Suboxone)
16 Relapse Prevention to Reduce HIV Among Women Prisoners Completed NCT00763958 Phase 4 Placebo;Buprenorphine
17 Counseling for Primary Care Office-based Buprenorphine Completed NCT00595764 Phase 4
18 Buprenorphine Maintenance vs. Detoxification in Prescription Opioid Dependence Completed NCT00555425 Phase 4
19 Effects of Ketamine On Precipitated Opioid Withdrawal Under General Anaesthesia Completed NCT00300794 Phase 4 Ketamine
20 Determine the Safety of a Sublingual Tablet Formulation of Buprenorphine and Naloxone by Extending the Combination Tablet Availability to Physicians in Office-Based Practice Completed NCT00007527 Phase 4 naloxone;buprenorphine
21 A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects (Study P04843)(COMPLETED) Completed NCT00605033 Phase 4 Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484;Subutex, Buprenorphine Hydrochloride, SCH 28444
22 A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users (P05042)(COMPLETED) Completed NCT00604188 Phase 4 Suboxone (SCH 000484);Subutex (SCH 028444)
23 Preference for Subutex® (Buprenorphine) Versus Suboxone® (Buprenorphine/Naloxone) in Opioid Dependent Patients on Subutex® (Study P05094)(COMPLETED) Completed NCT00684073 Phase 4 buprenorphine;buprenorphine/naloxone
24 Treatment of Polydrug-Using Opiate Dependents During Withdrawal Completed NCT00367874 Phase 4 Buprenorphine;Valproate
25 Desvenlafaxine in Opioid-Dependent Patients Completed NCT02200406 Phase 4 Desvenlafaxine
26 Buprenorphine/Naloxone in the Treatment of Heroin Dependence - 14 Completed NCT00015340 Phase 4 Buprenorphine/naloxone
27 Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients Completed NCT00879996 Phase 4 Methadone;Buprenorphine/naloxone
28 Attention Training for Opioid-maintained Cocaine Users Completed NCT01870882 Phase 4
29 Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral Therapy Completed NCT01045278 Phase 4 Pegylated interferon-alfa-2b and ribavirin
30 Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) Completed NCT00798538 Phase 4
31 Effects of Buspirone in Opiate Withdrawal Completed NCT00326235 Phase 4 Buspirone
32 A Stepwise Strategy Utilizing Buprenorphine and Methadone Completed NCT00310934 Phase 4 methadone;buprenorphine / methadone sequence
33 Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia Completed NCT02396979 Phase 4 Methadone
34 HIV, Buprenorphine, and the Criminal Justice System (STRIDE2) Completed NCT03583138 Phase 4 buprenorphine
35 Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry Recruiting NCT01999946 Phase 4 Extended-Release Naltrexone
36 Long Acting Naltrexone for Opioid Addiction: Focus on Sustained Abstinence and Recovery Recruiting NCT03647774 Phase 4 Extended release naltrexone
37 Houston Emergency Opioid Engagement System Recruiting NCT03396276 Phase 4 Suboxone
38 Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings Recruiting NCT03089983 Phase 4 Naltrexone;Methadone;Isoniazid;Rifapentine
39 A Pilot Study of Treating HCV at a Psychiatrist-staffed Outpatient Addiction Clinic Recruiting NCT03235154 Phase 4 sofosbuvir/velpatasvir
40 Trial of Injected Liposomal Bupivacaine vs Bupivacaine Infusion After Surgical Stabilization of Rib Fractures Recruiting NCT03305666 Phase 4 Liposomal bupivacaine injection;Bupivacaine indwelling catheter
41 Switch to Genvoya Followed by HCV Therapy With Epclusa in Patients With HIV/HCV Co-Infection on Methadone Recruiting NCT03549312 Phase 4 Genvoya;Epclusa
42 Structured Discontinuation vs Continued Therapy in Suboptimal and Optimal Responders to High-dose Long-term Opioids for Chronic Pain Active, not recruiting NCT02741076 Phase 4 Morphine Sulfate ER;Oxycodone ER;Oxymorphone ER
43 Biomarkers of Injectable Extended Release Naltrexone Treatment Active, not recruiting NCT02324725 Phase 4 Naltrexone
44 Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings Enrolling by invitation NCT02978417 Phase 4 Naltrexone for extended-release injectable suspension;Oral naltrexone
45 Opioids and Smoking Cessation Not yet recruiting NCT03857139 Phase 4 Nicotine patch
46 Pain Control Following Sinus Surgery Not yet recruiting NCT03783702 Phase 4 OxyCODONE 5 Mg Oral Tablet;Ibuprofen 600 Mg Oral Tablet;Acetaminophen 650 MG Oral Tablet
47 XRB vs. SLB in Jail and at Re-entry: Pilot, Proof of Concept Not yet recruiting NCT03604159 Phase 4 Buprenorphine Extended Release;Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets)
48 Can Simplified and More Detailed Instructions Affect Post-Operative Narcotic Consumption Not yet recruiting NCT03534102 Phase 4 Improved Opioid-Tapering Instructions
49 Gabapentin Regimens and Their Effects on Opioid Consumption Not yet recruiting NCT03334903 Phase 4 Gabapentin
50 Conversion to Embeda With Rescue Trial Terminated NCT01179191 Phase 4 morphine sulfate and naltrexone hydrochloride (EMBEDA)

Search NIH Clinical Center for Opioid Abuse

Cochrane evidence based reviews: opioid-related disorders

Genetic Tests for Opioid Abuse

Anatomical Context for Opioid Abuse

MalaCards organs/tissues related to Opioid Abuse:

42
Testes, Brain, Skin, Liver, Bone, Breast, Heart

Publications for Opioid Abuse

Articles related to Opioid Abuse:

(show top 50) (show all 288)
# Title Authors Year
1
Determinants of opioid abuse potential: Insights using intracranial self-stimulation. ( 30391425 )
2019
2
Association and Effect of Opioid Abuse-Related Readmission. ( 30550433 )
2019
3
The Prevalence and Cost of Medicare Beneficiaries Diagnosed and At Risk for Opioid Abuse, Dependence, and Poisoning. ( 30589633 )
2019
4
Causal inference for evaluating prescription opioid abuse using trend-in-trend design. ( 30714239 )
2019
5
Latest Opioid Abuse Bill Contains Over 100 Provisions But No Far-Reaching Pharmacy Mandates. ( 30766006 )
2019
6
Effectiveness and framing of pharmaceutical opioid abuse-deterrent formulations. ( 30767388 )
2019
7
Prevention of Opioid Abuse and Treatment of Opioid Addiction: Current Status and Future Possibilities. ( 30786212 )
2019
8
Non-pharmacological interventions for acute pain management in patients with opioid abuse or opioid tolerance: a scoping review protocol. ( 30864979 )
2019
9
America's Problem with Opioid Abuse Takes Its Toll on Nursing, Too. ( 30896481 )
2019
10
Long-term opioid users with chronic noncancer pain: Assessment of opioid abuse risk and relationship with healthcare resource use. ( 29733099 )
2018
11
Causal Analysis in Evaluating Complex Health Interventions: Identifying the Optimal Treatment for Opioid Abuse in Pregnancy. ( 29572908 )
2018
12
The prescription opioid abuse crisis and our role in it. ( 29964241 )
2018
13
The Public and the Opioid-Abuse Epidemic. ( 29298128 )
2018
14
Blocking interleukin-4 enhances efficacy of vaccines for treatment of opioid abuse and prevention of opioid overdose. ( 29615715 )
2018
15
The role of managed care professionals and pharmacists in combating opioid abuse. ( 29851451 )
2018
16
Opioid Abuse or Dependence Increases 30-day Readmission Rates after Major Operating Room Procedures: A National Readmissions Database Study. ( 29470180 )
2018
17
Tramadol (opioid) abuse is associated with a dose- and time-dependent poor sperm quality and hyperprolactinaemia in young men. ( 29781510 )
2018
18
The FDA's Latest Response to Opioid Abuse and Overdose. ( 29280800 )
2018
19
Opioid Abuse and Death: Thoughts From Dayton, Ohio. ( 29933441 )
2018
20
Post-marketing studies of pharmaceutical opioid abuse-deterrent formulations: a framework for research design and reporting. ( 29989247 )
2018
21
Risks of opioid abuse among uninsured primary care patients utilizing a free clinic. ( 30040586 )
2018
22
Letter to the Editor: A Case for Opioid Education and Training for Medical Students, Residents, and Allied Health Staff: Response to "Educational Intervention for Physicians to address the risk of Opioid Abuse". ( 30044479 )
2018
23
Ethical dimensions of the prescription opioid abuse crisis. ( 30045851 )
2018
24
Management Strategies in Opioid Abuse and Sexual Dysfunction: A Review of Opioid-Induced Androgen Deficiency. ( 30057139 )
2018
25
Opioid abuse/dependence among those hospitalized due to periapical abscess. ( 30066389 )
2018
26
Prevalence of Emergency Department Patients Presenting with Heroin or Prescription Opioid Abuse Residing in Urban, Suburban, and Rural Jefferson County. ( 30253947 )
2018
27
Risk of behaviour suggestive of opioid abuse: a protocol for a systematic review of validated assessment tools. ( 30282680 )
2018
28
Opioid Abuse and Dependence in Those Hospitalized Due to Head and Neck Cancer. ( 30509393 )
2018
29
Promoting opioid overdose prevention and recovery: An exploratory study of an innovative intervention model to address opioid abuse. ( 30551002 )
2018
30
The natural history of prescription opioid abuse: A pilot study exploring change in routes of administration and motivation for changes. ( 30629276 )
2018
31
Chronic pain and opioid abuse: Factors associated with health-related quality of life. ( 29160596 )
2017
32
Interprofessional prescription opioid abuse communication among prescribers and pharmacists: A qualitative analysis. ( 28799863 )
2017
33
Toolkit aims to make adolescents aware of dangers of opioid abuse. ( 28483935 )
2017
34
The Economic Burden of Opioid Abuse: Updated Findings. ( 28345440 )
2017
35
Screening tools to assess risk of opioid abuse in the Canadian primary healthcare setting. ( 28346282 )
2017
36
Prescription Opioid Abuse in Chronic Pain: An Updated Review of Opioid Abuse Predictors and Strategies to Curb Opioid Abuse (Part 2). ( 28226334 )
2017
37
Review of Factors, Methods, and Outcome Definition in Designing Opioid Abuse Predictive Models. ( 29016966 )
2017
38
The Use of Continuous Ketamine for Analgesia and Sedation in Critically Ill Patients with Opioid Abuse: A Case Series. ( 29967888 )
2017
39
Collaboration Needed: Pain Care and Opioid Abuse. ( 27681886 )
2017
40
Prescription opioid abuse in prison settings: A systematic review of prevalence, practice and treatment responses. ( 28086177 )
2017
41
Medical outcomes associated with prescription opioid abuse via oral and non-oral routes of administration. ( 28414990 )
2017
42
"I am in pain": is it really the magic formula to open the door of opioid abuse? ( 28726366 )
2017
43
Opioid Abuse And Poisoning: Trends In Inpatient And Emergency Department Discharges. ( 28971919 )
2017
44
Epidemiology of Opioid Abuse and Addiction. ( 28372767 )
2017
45
The ALERRT(Ar) instrument: a quantitative measure of the effort required to compromise prescription opioid abuse-deterrent tablets. ( 28448223 )
2017
46
Treating postoperative pain in the patient who is in recovery or remission from opioid abuse: Focus on Tapentadol. ( 29441514 )
2017
47
Prescription Opioid Abuse in Chronic Pain: An Updated Review of Opioid Abuse Predictors and Strategies to Curb Opioid Abuse: Part 1. ( 28226333 )
2017
48
You never know when you'll need a Vicodin: An era of opioid abuse. ( 28400252 )
2017
49
Drivers of excess costs of opioid abuse among a commercially insured population. ( 28738684 )
2017
50
Corrigendum: The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting. ( 28318019 )
2017

Variations for Opioid Abuse

Expression for Opioid Abuse

Search GEO for disease gene expression data for Opioid Abuse.

Pathways for Opioid Abuse

GO Terms for Opioid Abuse

Cellular components related to Opioid Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 dendrite GO:0030425 9.67 CCK OPRK1 OPRM1 PDYN
2 neuronal cell body GO:0043025 9.56 CCK GRIN3B OPRK1 PDYN
3 perikaryon GO:0043204 9.5 CCK OPRK1 OPRM1
4 integral component of postsynaptic membrane GO:0099055 9.46 OPRK1 OPRM1
5 integral component of synaptic vesicle membrane GO:0030285 9.43 OPRD1 OPRK1
6 dendrite membrane GO:0032590 9.4 OPRD1 OPRM1
7 integral component of presynaptic membrane GO:0099056 9.33 OPRD1 OPRK1 OPRM1
8 axon terminus GO:0043679 9.13 OPRD1 OPRK1 PDYN
9 spine apparatus GO:0097444 8.62 OPRD1 OPRM1

Biological processes related to Opioid Abuse according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 9.97 CCK OPRD1 OPRK1 OPRL1 OPRM1 PDYN
2 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.65 OPRD1 OPRK1 OPRM1
3 neuropeptide signaling pathway GO:0007218 9.65 OPRD1 OPRK1 OPRL1 OPRM1 PDYN
4 sensory perception of pain GO:0019233 9.63 OPRK1 OPRL1 OPRM1
5 adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway GO:0007193 9.62 OPRD1 OPRK1 OPRL1 OPRM1
6 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.59 OPRD1 OPRM1
7 response to cocaine GO:0042220 9.58 OPRK1 OPRM1
8 response to radiation GO:0009314 9.58 OPRK1 OPRM1
9 estrous cycle GO:0044849 9.58 OPRK1 OPRL1 OPRM1
10 response to morphine GO:0043278 9.57 OPRK1 OPRM1
11 regulation of calcium ion transport GO:0051924 9.56 GRIN3B OPRD1
12 behavior GO:0007610 9.54 OPRK1 OPRL1
13 sensory perception GO:0007600 9.54 OPRK1 OPRL1 OPRM1
14 positive regulation of sensory perception of pain GO:1904058 9.52 CCK OPRL1
15 negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway GO:0106072 9.51 OPRL1 OPRM1
16 opioid receptor signaling pathway GO:0038003 9.46 OPRD1 OPRK1 OPRL1 OPRM1
17 adenylate cyclase-inhibiting opioid receptor signaling pathway GO:0031635 9.43 OPRK1 OPRM1
18 regulation of sensory perception of pain GO:0051930 9.35 CCK OPRD1 OPRK1 OPRL1 OPRM1
19 eating behavior GO:0042755 9.02 CCK OPRD1 OPRK1 OPRL1 OPRM1
20 signal transduction GO:0007165 10.02 CCK MAPK10 OPRD1 OPRK1 OPRL1 OPRM1

Molecular functions related to Opioid Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.56 OPRD1 OPRK1 OPRL1 OPRM1
2 neuropeptide binding GO:0042923 9.26 OPRD1 OPRK1 OPRL1 OPRM1
3 receptor serine/threonine kinase binding GO:0033612 9.16 OPRD1 OPRK1
4 opioid receptor activity GO:0004985 8.92 OPRD1 OPRK1 OPRL1 OPRM1

Sources for Opioid Abuse

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....